Injective: Nasdaq approves Canary Capital's ETF listing - 04 Nov 2026
Nasdaq has approved the listing of Canary Capital's Injective ETF on November 4, 2026. The ETF gives INJ its first regulated exchange-traded product in the United States.The ETF opens a new institutional demand channel for INJ. Traditional investors gain an exchange-traded route to the token through Canary Capital's product, bringing access to INJ into the regulated US securities market.⚡️ JUST IN: Nasdaq has approved the listing of Canary Capital’s Injective ETF featuring staking rewards.